Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

We investigated the prevalence of dyskinesias and motor fluctuations, and the factors determining their occurrence, in a community-based population of patients with Parkinson's disease. Among 124 patients with Parkinson's disease, 87 (70%) had received a levodopa preparation. Among these 87 patients, 28% were experiencing treatment-induced dyskinesias and 40% response fluctuations. The prevalence of motor fluctuations was best predicted by disease duration and dose of levodopa, whereas dyskinesias could be best predicted by duration of treatment. Patients with a shorter time from symptom onset to initiation of levodopa and younger patients had developed motor complications earlier, and patients who had started treatment with a dopamine agonist had developed these treatment complications later. Although a satisfactory response to medication was associated with higher rates of motor complications, poor or moderate response was associated with lower quality of life in patients with a disease duration of </=5 years or >/=10 years. We conclude that motor fluctuations are most strongly related to disease duration and dose of levodopa, and dyskinesias to duration of levodopa treatment. However, poorer quality of life associated with inadequate dosage of levodopa may be the price for a low rate of motor complications in patients with Parkinson's disease.

[1]  J. Montastruc.  Treatment of Parkinson's disease should begin with a dopamine agonist , 2000, Movement disorders : official journal of the Movement Disorder Society.

[2]  S. Fahn.  Unified Parkinson's Disease Rating Scale , 1987 .

[3]  Y Ben-Shlomo,et al.  Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study , 1999, The Lancet.

[4]  C. Marsden,et al.  SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASE , 1977, The Lancet.

[5]  T. Riise,et al.  The epidemiology of Parkinson's disease in the county of Rogaland, Norway , 1995, Movement disorders : official journal of the Movement Disorder Society.

[6]  O. Rascol,et al.  A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[7]  V. Kostic,et al.  Early development of levodopa‐induced dyskinesias and response fluctuations in young‐onset Parkinson's disease , 1991, Neurology.

[8]  C. Marsden,et al.  Recent Developments in Parkinson's Disease , 1986 .

[9]  A. Tröster,et al.  Motor Complications of Chronic Levodopa Therapy in Parkinson's Disease , 1997, Clinical neuropharmacology.

[10]  Y. Agid,et al.  Does levodopa aggravate Parkinson's disease? , 1988, Neurology.

[11]  Y Ben-Shlomo,et al.  Cross sectional prevalence survey of idiopathic Parkinson's disease and parkinsonism in London , 2000, BMJ : British Medical Journal.

[12]  M. Yahr,et al.  Comparative study of selegiline plus L‐dopa–carbidopa versus L‐dopa–carbidopa alone in the treatment of parkinson's disease , 1995, Annals of neurology.

[13]  C. Markham,et al.  Long‐term follow‐up of early dopa treatment in Parkinson's disease , 1986, Annals of neurology.

[14]  F. Mcdowell,et al.  “Early” initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease , 1991, Neurology.

[15]  J. Langston,et al.  Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) , 1985, Neurology.

[16]  G. Block,et al.  Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. , 1997, European neurology.

[17]  S. Fahn.  Adverse Effects of Levodopa in Parkinson’s Disease , 1989 .

[18]  E. van der Velde,et al.  Response fluctuations in Parkinson's disease , 1990, Neurology.

[19]  A. Tröster,et al.  Gender differences in Parkinson's disease. , 1998, Clinical neuropharmacology.

[20]  R P Lesser,et al.  Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapy , 1979, Neurology.

[21]  H. Pakkenberg,et al.  Sustained‐release Madopar HBS® compared with standard Madopar® in the long‐term treatment of de novo parkinsonian patients , 1996, Acta neurologica Scandinavica.

[22]  W. Gibb,et al.  THE SIGNIFICANCE OF THE LEWY BODY IN THE DIAGNOSIS OF IDIOPATHIC PARKINSON'S DISEASE , 1989, Neuropathology and applied neurobiology.

[23]  J. Meerwaldt,et al.  Factors that influence the occurrence of response variations in Parkinson's disease , 1987, Annals of neurology.

[24]  W. Weiner.  The initial treatment of Parkinson's disease should begin with levodopa , 1999, Movement disorders : official journal of the Movement Disorder Society.

[25]  A. Lang,et al.  Parkinson's disease. Second of two parts. , 1998, The New England journal of medicine.

[26]  D. Brooks,et al.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.

[27]  W. Poewe,et al.  Low‐dose L‐dopa therapy in Parkinson's disease , 1986, Neurology.

[28]  M. Pederzoli,et al.  L‐dopa long‐term treatment in Parkinson's disease , 1983, Neurology.

[29]  T. Raju.  The Nobel Chronicles , 1999, The Lancet.

[30]  W R Woodward,et al.  Motor fluctuations in parkinson's disease , 1989, Annals of neurology.

[31]  S. Iversen,et al.  Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. , 1990, Clinical neuropharmacology.

[32]  G. Broe,et al.  The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[33]  E. Melamed.  Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease. , 1986, Archives of neurology.

[34]  R. Robertson,et al.  Induction of chorea and dystonia in parkinsonian primates , 1990, Movement disorders : official journal of the Movement Disorder Society.

[35]  J. Schneider.  Levodopa-induced dyskinesias in parkinsonian monkeys: Relationship to extent of nigrostriatal damage , 1989, Pharmacology Biochemistry and Behavior.

[36]  F. Mcdowell,et al.  Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients. , 1975, Annals of internal medicine.

[37]  U. Rinne.  Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease , 1987, Neurology.

[38]  Anthony E. Lang,et al.  Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa , 1996 .

[39]  S. Fahn,et al.  Should Levodopa Therapy for Parkinsonism be Started Early or Late? Evidence Against Early Treatment , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[40]  S. Fahn.  Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .